{"record_type":"pith_number_record","schema_url":"https://pith.science/schemas/pith-number/v1.json","pith_number":"pith:2025:F4P6LVJW6BDBIB33DHEM4UH65X","short_pith_number":"pith:F4P6LVJW","schema_version":"1.0","canonical_sha256":"2f1fe5d536f04614077b19c8ce50feedc775c8d2f30f9dd7a7a276f4f5d7d4ee","source":{"kind":"arxiv","id":"2509.04939","version":1},"attestation_state":"computed","paper":{"title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","headline":"","cross_cats":[],"primary_cat":"q-bio.QM","authors_text":"APHM), Audrey Boutonnet, COMPO), Frederic Fina, Fr\\'ed\\'eric Ginot, Jean-Charles Garcia, Jean-Laurent Deville (TIMONE), Laurent Greillier (COMPO, Linh Nguyen Phuong (COMPO), Lucie Della-Negra (COMPO), Pascale Tomasini (APHM, Romain Zakrasjek (COMPO), S\\'ebastien Benzekry (COMPO), S\\'ebastien Salas (COMPO, TIMONE)","submitted_at":"2025-09-05T09:01:43Z","abstract_excerpt":"Background: Many advanced cancer patients experience progression under immune-checkpoint inhibitors (ICIs). Circulating cell-free DNA (cfDNA) size profiles offer a promising noninvasive multi-cancer approach to monitor and predict immunotherapy response. Methods: In the SChISM (Size CfDNA Immunotherapy Signature Monitoring) study (NCT05083494), pre-treatment plasmatic cfDNA size profiles from 126 ICI-treated advanced carcinomas were quantified using the BIABooster device. Fragmentomederived variables (concentration, peaks' position, and fragment size ranges) at baseline were analyzed for assoc"},"verification_status":{"content_addressed":true,"pith_receipt":true,"author_attested":false,"weak_author_claims":0,"strong_author_claims":0,"externally_anchored":false,"storage_verified":false,"citation_signatures":0,"replication_records":0,"graph_snapshot":true,"references_resolved":false,"formal_links_present":false},"canonical_record":{"source":{"id":"2509.04939","kind":"arxiv","version":1},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.QM","submitted_at":"2025-09-05T09:01:43Z","cross_cats_sorted":[],"title_canon_sha256":"b39cf2446cebe260a236a2194e756e8cb6073fde1d1982246563e670d1a348a4","abstract_canon_sha256":"345a1195150274b557247889b56cf989ee7c5dcb1f5243f70ef4354c64dfc8e5"},"schema_version":"1.0"},"receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-07-05T12:05:32.626958Z","signature_b64":"Mi0u5k+TzX0jK3sUhxHcxAKEogzqc8U/qQ0lEemXPaXHtjBAbi+GOKDBeZZOF3ucuL71D9rygcUSn0peMixWCg==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"2f1fe5d536f04614077b19c8ce50feedc775c8d2f30f9dd7a7a276f4f5d7d4ee","last_reissued_at":"2026-07-05T12:05:32.626441Z","signature_status":"signed_v1","first_computed_at":"2026-07-05T12:05:32.626441Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"graph_snapshot":{"paper":{"title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","headline":"","cross_cats":[],"primary_cat":"q-bio.QM","authors_text":"APHM), Audrey Boutonnet, COMPO), Frederic Fina, Fr\\'ed\\'eric Ginot, Jean-Charles Garcia, Jean-Laurent Deville (TIMONE), Laurent Greillier (COMPO, Linh Nguyen Phuong (COMPO), Lucie Della-Negra (COMPO), Pascale Tomasini (APHM, Romain Zakrasjek (COMPO), S\\'ebastien Benzekry (COMPO), S\\'ebastien Salas (COMPO, TIMONE)","submitted_at":"2025-09-05T09:01:43Z","abstract_excerpt":"Background: Many advanced cancer patients experience progression under immune-checkpoint inhibitors (ICIs). Circulating cell-free DNA (cfDNA) size profiles offer a promising noninvasive multi-cancer approach to monitor and predict immunotherapy response. Methods: In the SChISM (Size CfDNA Immunotherapy Signature Monitoring) study (NCT05083494), pre-treatment plasmatic cfDNA size profiles from 126 ICI-treated advanced carcinomas were quantified using the BIABooster device. Fragmentomederived variables (concentration, peaks' position, and fragment size ranges) at baseline were analyzed for assoc"},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"2509.04939","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"integrity":{"clean":true,"summary":{"advisory":0,"critical":0,"by_detector":{},"informational":0},"endpoint":"/pith/2509.04939/integrity.json","findings":[],"available":true,"detectors_run":[],"snapshot_sha256":"c28c3603d3b5d939e8dc4c7e95fa8dfce3d595e45f758748cecf8e644a296938"},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"aliases":[{"alias_kind":"arxiv","alias_value":"2509.04939","created_at":"2026-07-05T12:05:32.626508+00:00"},{"alias_kind":"arxiv_version","alias_value":"2509.04939v1","created_at":"2026-07-05T12:05:32.626508+00:00"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.2509.04939","created_at":"2026-07-05T12:05:32.626508+00:00"},{"alias_kind":"pith_short_12","alias_value":"F4P6LVJW6BDB","created_at":"2026-07-05T12:05:32.626508+00:00"},{"alias_kind":"pith_short_16","alias_value":"F4P6LVJW6BDBIB33","created_at":"2026-07-05T12:05:32.626508+00:00"},{"alias_kind":"pith_short_8","alias_value":"F4P6LVJW","created_at":"2026-07-05T12:05:32.626508+00:00"}],"events":[],"event_summary":{},"paper_claims":[],"inbound_citations":{"count":0,"internal_anchor_count":0,"sample":[]},"formal_canon":{"evidence_count":0,"sample":[],"anchors":[]},"links":{"html":"https://pith.science/pith/F4P6LVJW6BDBIB33DHEM4UH65X","json":"https://pith.science/pith/F4P6LVJW6BDBIB33DHEM4UH65X.json","graph_json":"https://pith.science/api/pith-number/F4P6LVJW6BDBIB33DHEM4UH65X/graph.json","events_json":"https://pith.science/api/pith-number/F4P6LVJW6BDBIB33DHEM4UH65X/events.json","paper":"https://pith.science/paper/F4P6LVJW"},"agent_actions":{"view_html":"https://pith.science/pith/F4P6LVJW6BDBIB33DHEM4UH65X","download_json":"https://pith.science/pith/F4P6LVJW6BDBIB33DHEM4UH65X.json","view_paper":"https://pith.science/paper/F4P6LVJW","resolve_alias":"https://pith.science/api/pith-number/resolve?arxiv=2509.04939&json=true","fetch_graph":"https://pith.science/api/pith-number/F4P6LVJW6BDBIB33DHEM4UH65X/graph.json","fetch_events":"https://pith.science/api/pith-number/F4P6LVJW6BDBIB33DHEM4UH65X/events.json","actions":{"anchor_timestamp":"https://pith.science/pith/F4P6LVJW6BDBIB33DHEM4UH65X/action/timestamp_anchor","attest_storage":"https://pith.science/pith/F4P6LVJW6BDBIB33DHEM4UH65X/action/storage_attestation","attest_author":"https://pith.science/pith/F4P6LVJW6BDBIB33DHEM4UH65X/action/author_attestation","sign_citation":"https://pith.science/pith/F4P6LVJW6BDBIB33DHEM4UH65X/action/citation_signature","submit_replication":"https://pith.science/pith/F4P6LVJW6BDBIB33DHEM4UH65X/action/replication_record"}},"created_at":"2026-07-05T12:05:32.626508+00:00","updated_at":"2026-07-05T12:05:32.626508+00:00"}